argenx
Focus: argenx is a Belgium-based antibody-focused biotech specializing in autoimmune, neurological, and oncology treatments, with a commercial footprint anchored by VYVGART, its approved Fc receptor blocker.
Profile data last refreshed 13h ago · AI intelligence enriched 1mo ago
Open Jobs
45-4 this month
Stable — net -4 jobs in 30d
18 added, 22 removed. Backfill posture.
Should You Work at argenx?
AI assessmentSolid mid-stage biotech with a validated commercial franchise and meaningful pipeline depth—suitable for professionals seeking stability and clinical advancement, but requires comfort with single-asset revenue dependency.
Why Work Here
- Clear commercial momentum: VYVGART generated ~$200M in Part D spending and has a subcutaneous formulation (HYTRULO) in growth phase, reducing revenue concentration risk.
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Lead revenue driver (96% of total) with established efficacy in autoimmune settings and active Phase 3 expansion programs.
Help build intelligence for argenx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.